Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Dr. Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Doctor at Ministry of Health | Spain

Dr. Pedro Moltó-Balado is a dedicated medical professional currently associated with the Ministry of Health, Spain. With a background in family and community medicine, he has combined clinical expertise with research innovation to advance patient care processes and public health initiatives. He has pursued advanced studies in biomedicine, patient care management, and headache specialization while contributing extensively to scientific publications across medical disciplines. His work encompasses cardiovascular health, mental health, primary care innovations, and clinical risk assessment, with a strong commitment to integrating machine learning and advanced diagnostic strategies in healthcare to enhance patient outcomes and medical decision-making.

Publication Profile 

Orcid

Education 

Dr. Pedro Moltó-Balado holds a Graduate in Medicine from Terres de l’Ebre Teaching Unit, Catalonia, Spain. He specialized in Family and Community Medicine through Francisco de Vitoria University and pursued a Ph.D. in Biomedicine from Rovira i Virgili University. Additionally, he completed postgraduate certifications as a University Expert in Headaches and in the Management of Patient Care Processes from Jaime I University and the University of Valencia, respectively. He has undergone specialized health training and participated in continuous academic development across medical law, healthcare management, and clinical research, strengthening his expertise in multidisciplinary healthcare and evidence-based medical practices.

Experience 

Dr. Pedro Moltó-Balado has been actively involved in healthcare practice and academic research through the Ministry of Health and academic institutions in Spain. He has contributed as a corresponding author and researcher in multiple peer-reviewed scientific journals, focusing on primary care innovations, cardiometabolic diseases, and neurological conditions. His professional engagements include clinical research in atrial fibrillation, stroke prevention, metabolic disorders, and rare medical conditions, along with implementing patient-centered healthcare strategies. He has also participated in academic teaching, supervising research projects, and contributing to medical education programs while collaborating with healthcare organizations to translate clinical research into practical healthcare solutions.

Awards and Honors 

Dr. Pedro Moltó-Balado has been recognized for his research contributions and academic excellence in family and community medicine, cardiometabolic health, and primary care innovation. His work on early diagnosis in cardiovascular medicine, clinical risk prevention, and rare disease case studies has been acknowledged through conference presentations, academic collaborations, and peer-reviewed scientific publications. He has contributed to international research forums and interdisciplinary projects that integrate clinical practice with technological innovation, including machine learning applications in healthcare. His commitment to advancing evidence-based medical practices has earned him recognition in medical research communities focused on improving public health outcomes.

Research Focus 

Dr. Pedro Moltó-Balado’s research focuses on cardiovascular risk prediction, primary care optimization, and integrating technology into clinical diagnostics. His studies explore early detection of atrial fibrillation, stroke prevention strategies, metabolic disorders, and neurological complications in primary healthcare settings. He has worked on machine learning models for predicting major adverse cardiovascular events, case studies on rare conditions such as pheochromocytoma and rhinocerebral mucormycosis, and management approaches for psychiatric medication complications. His multidisciplinary approach bridges clinical medicine, data analytics, and patient care strategies, aiming to develop innovative diagnostic tools and risk assessment methods that improve healthcare decision-making and patient safety outcomes.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Algo más que una coxalgia: necrosis avascular de cabeza femoral

Aripiprazole: Beware of pathological gambling addiction,Aripiprazol: cuidado con la adicción patológica al juego

Mucormicosis tras una picadura de araña

The Future of Healthcare: Biomedical Technology and Integrated Artificial Intelligence

Oleoma glúteo: consecuencias del tratamiento intramuscular

Machine Learning Approaches to Predict Major Adverse Cardiovascular Events in Atrial Fibrillation

Conclusion

Dr. Pedro Moltó-Balado’s academic achievements, innovative research in cardiometabolic and primary care medicine, and integration of technology into clinical diagnostics make him a highly suitable candidate for the Best Researcher Award. His dedication to improving patient outcomes through evidence-based research and his contributions to medical literature align well with the award’s objectives. With continued emphasis on global collaborations and translational research, his work has the potential to make significant advancements in public health and medical science.

Maria Garrido | Personalized Medicine | Women Researcher Award

Dr. Maria Garrido | Personalized Medicine | Women Researcher Award

Doctor at Hospital Universidtario 12 de octubre-Universidad Complutense de Madrid | Spain

Dr. Maria Garrido is a physician-scientist specializing in pathology and translational oncology with a focus on melanoma and cutaneous lymphomas. She earned her medical degree from the University of Granada and her PhD in Health Sciences and Biomedicine from Universidad Complutense de Madrid. With extensive international experience at the University of California San Francisco and Memorial Sloan Kettering, her research has contributed to landmark discoveries in oncogenes, fusion kinases, and tumor biomarkers. She currently works in dermatopathology and oncology research, collaborating with leading groups in Europe and internationally to advance personalized cancer diagnostics and therapeutic strategies.

Publication Profile 

Orcid

Education 

Dr. Maria Garrido obtained her medical degree in Medicine and Surgery from the University of Granada. She pursued her residency in Anatomical Pathology at Hospital Universitario 12 de Octubre, Madrid, and later completed a PhD in Health Sciences and Biomedicine at Universidad Complutense de Madrid. Complementing her medical and scientific training, she earned a Master’s in Clinical Management, Medical, and Healthcare Leadership from Universidad Tecnológica. Her academic formation integrates rigorous clinical foundations with molecular oncology research, allowing her to bridge patient care and translational science. She has continued to enhance her expertise through national and international academic fellowships.

Experience 

Dr. Maria Garrido has served as a resident and clinical specialist in pathology at major Spanish hospitals, including Hospital 12 de Octubre, Hospital General de Móstoles, and Clinic Hospital of Barcelona. Internationally, she was a fellowship researcher at UCSF and Memorial Sloan Kettering, contributing to melanoma genetics and translational oncology. She has collaborated on groundbreaking discoveries, including oncogenes in uveal melanoma and fusion kinases in Spitz tumors. Currently, she is part of the dermatopathology and oncology research group at Hospital Universitario 12 de Octubre, Madrid, where she advances studies on melanoma, lymphomas, molecular biomarkers, and diagnostic innovations in cutaneous oncology.

Awards and Honors 

Dr. Maria Garrido has received notable recognition for her research contributions. She was awarded a mobility fellowship by the Spanish Ministry of Science and Innovation for professional development in computational pathology at Queen’s University, Belfast. Her discoveries, including the GNA11 oncogene and fusion kinases in melanocytic tumors, have been published in high-impact journals such as the New England Journal of Medicine, Nature Communications, and Nature Genetics. Her contributions to the field of melanoma genetics have been cited worldwide, shaping the understanding of tumor biology. She continues to be honored through invitations to collaborate on international research initiatives and networks.

Research Focus 

Dr. Maria Garrido research focuses on the molecular pathology of melanoma and cutaneous lymphomas. She has made significant contributions to identifying oncogenes such as GNA11 and GNAQ, which account for most uveal melanomas, and discovering kinase fusion proteins in Spitz tumors. Her work also includes genetic studies on desmoplastic melanoma highlighting NFKBIE mutations. More recently, she has contributed to refining the classification of cutaneous lymphomas and identifying new biomarkers to guide diagnosis, prognosis, and therapeutic response. Her approach integrates pathology, molecular biology, and translational medicine to improve personalized treatment strategies and enhance patient outcomes in oncology and dermatopathology.

Publication Top Notes

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Acute sarcoidosis as a harbinger for pancreatic adenocarcinoma

TERT promoter mutation in sebaceous neoplasms

Orbital Solitary Fibrous Tumor: Four Case Reports—Clinical and Histopathological Features

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma